Daptomycin-induced eosinophilia without pulmonary involvement

Doan, Thien-Ly; DePetrillo, John; Singer, Carol
December 2010
American Journal of Health-System Pharmacy;12/15/2010, Vol. 67 Issue 24, p2107
Academic Journal
Case Study
Purpose. The case of a patient who developed peripheral eosinophilia associated with the use of daptomycin is described. Summary. A 63-year-old man with a history of rheumatic fever during childhood arrived at the emergency department with a chief complaint of left knee pain and swelling. One week before his arrival, the patient received a corticosteroid injection for worsening pain, with minimal relief. The patient's medical history also included type 2 diabetes mellitus, hypertension, coronary artery disease, and hypercholesterolemia. The patient had a documented allergy to cephalexin (skin rash). His initial white blood cell (WBC) count was 16,500 cells/mm3 (normal, 4,000-10,600 cells/mm3), with 89% neutrophils (normal, 40-80%), 5.6% lymphocytes (normal,15-45%), and 0% eosinophils (normal, 0-6%). On hospital day 2, blood cultures and aspiration cultures from the patient's knee were positive for methicillin-sensitive Staphylococcus aureus. Nafcillin and gentamicin were initiated, but on hospital day 7 the patient developed a diffuse, pruritic, macular rash believed to be secondary to nafcillin. At this point, nafcillin treatment was discontinued and daptomycin was initiated. Six days into his treatment, a routine complete blood count revealed a WBC count of 7,620 cells/mm3, with 11.8% eosinophils. The eosinophils continued to increase, peaking at 34.1% after 26 days of treatment with daptomycin. After cessation of daptomycin, the peripheral eosinophilia resolved. At no point during his hospitalization did the patient have evidence of pulmonary involvement. Conclusion. A 63-year-old man developed peripheral eosinophilia without evidence of pulmonary involvement while being treated with daptomycin.


Related Articles

  • Daptomycin use in pediatric patients. DURAND, CHERYL; BRUECKNER, ANDREW; SAMPADIAN, CHELSEA; WILLETT, KRISTINE C.; BELLIVEAU, PAUL // American Journal of Health-System Pharmacy;7/15/2014, Vol. 71 Issue 14, p1177 

    Purpose. Currently available evidence on the use of daptomycin in pediatric patients is reviewed and evaluated. Summary. Although guidelines on the treatment of methicillin-resistant Staphylococcus aureus infections recommend daptomycin for use in pediatric patients, that recommendation is...

  • MRSA INFECTIONS: The use of vancomycin and alternative drugs. BORCHARDT, ROY A.; ROLSTON, KENNETH V. I. // JAAPA: Journal of the American Academy of Physician Assistants (;Jun2012, Vol. 25 Issue 6, p22 

    The article discusses suitable treatments for Methicillin-resistant Staphylococcus aureus (MRSA), a frequent cause of serious infections, such as pneumonia, bacteremia, endocarditis and osteomyelitis. With reports of clinical failure with vancomycin therapy, consideration of alternative drugs...

  • Pilot Study Comparing Daptomycin And Telavancin In The Treatment Of Skin And Soft Tissue Infections. Evers, R.; Antony, N. I.; Alozie, O.; Antony, S. // Internet Journal of Infectious Diseases;2013, Vol. 12 Issue 2, p1 

    This is a prospective controlled, single blinded, randomized study comparing the efficacy and side effects of daptomycin and telavancin in patients with lower extremity skin and soft tissue infections (SSTI). Forty patients were enrolled with similar SSTI of the lower extremities and received...

  • Safety and Efficacy of Daptomycin in the Treatment of Gram-Positive Pathogens. Kelesidis, Theodoros // Clinical Medicine Insights: Therapeutics;2011, Issue 3, p403 

    Daptomycin is an antibacterial agent with activity against Gram-positive organisms and is a reliable option for the treatment of invasive Gram-positive infections. Daptomycin has been approved for the treatment of complicated skin and skin-structure infections and bacteremia including...

  • Erratum to “Induction of maggot antimicrobial peptides and treatment effect in Salmonella pullorum-infected chickens” (J. Appl. Poult. Res. 23:376–383). Zhou, Gang; Wang, Jungang; Zhu, Xiaoqi; Wu, Yufei; Gao, Mingming; Shen, Hong // Journal of Applied Poultry Research;Dec2014, Vol. 23 Issue 4, p792 

    A correction to the article "Induction of maggot antimicrobial peptides and treatment effect in Salmonella pullorum-infected chickens" that was published in the 2014 issue is presented.

  • Antimicrobial peptides as anticancer agents. Grigolava, M.; Vishnepolsky, B.; Pirtskhalava, M. // Biopolymers & Cell;2015 Suppl. 5, p6 

    Laboratory of Bioinformatics of I. Beritashvili Center of Experimental Biomedicine There is a considerable interest in developing anticancer agents with new mode of action. Many natural or synthetic cationic peptides have been reported to show anticancer activity. They are united in a separate...

  • Hepatorenal syndrome precipitated by infective endocarditis. Patel, Peysh A.; Lowe, Emma; Baig, Wazir; Sandoe, Jonathan // British Journal of Hospital Medicine (17508460);Sep2011, Vol. 72 Issue 9, p532 

    The article discusses a case study of a 67-year old man who presented to the emergency department (ED) with intermittent pyrexia, rigors and weight loss, and a history of sepsis and liver cirrhosis. He was started on vancomycin and rifampicin after blood culture was positive for Staphylococcus...

  • The Presence of Arginine in the Pro-Arg-Pro Motif Augments the Lethality of Proline Rich Antimicrobial Peptides of Insect Source. Lele, Deepti; Talat, Sariya; Kaur, Kanwal // International Journal of Peptide Research & Therapeutics;Dec2013, Vol. 19 Issue 4, p323 

    Antimicrobial peptides are emerging as alternate drug candidates over couple of decades. The diversity exists in amino acid sequence, conformation and mechanism of action of these peptides. Cationic antimicrobial peptides constitute major class which is further classified depending on abundance...

  • Antimicrobial peptides and their potential application in inflammation and sepsis. Schuerholz, Tobias; Brandenburg, Klaus; Marx, Gernot // Critical Care;2012, Vol. 16 Issue 2, p11220 

    The article discusses the potential application of antimicrobial peptides (AMPs) in treating inflammation and sepsis. Topics include obstacles to the administration of AMPs, such as their high toxicity, naturally occurring AMPs in inflammation, and the development of synthetic AMPs and their...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics